NKGen Biotech Presented Phase I Clinical Trial Data at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
October 26, 2023 08:00 ET
|
NKGen Biotech, Inc.
90% of patients demonstrated improvement or maintained stable cognitive function as per Alzheimer's disease composite score (ADCOMS) following 11 weeks SNK01 given intravenously (IV) appears to cross...
NKGen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease
October 24, 2023 08:00 ET
|
NKGen Biotech, Inc.
NKGen’s neurodegenerative program continues to advance with dosing in the Phase 1/2a clinical trial anticipated to commence by year-end 2023 NKGen’s SNK01 program continues to show positive...
NKGen Biotech Announces Poster Presentation at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
October 19, 2023 08:00 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and...
NKGen Biotech Presents Interim Phase I Trial Data at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023
October 17, 2023 08:00 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and...
NKGen Announces Poster Presentation at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023
October 11, 2023 08:00 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and...
NKGen Biotech, Inc. Announces Closing of Business Combination
October 02, 2023 08:00 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of...
NKGen Biotech to Present at the Cantor Fitzgerald Global Healthcare Conference 2023
September 21, 2023 14:15 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of...
Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023
August 30, 2023 07:00 ET
|
NKGen Biotech, Inc.
THE WOODLANDS, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Graf Acquisition Corp. IV (NYSE: GFOR, GFOR-UN, GFOR-WT) (the “Company” or “Graf”), announced today that it intends to adjourn, without...
NKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical Trial of SNK02, Allogeneic NK Cell Therapy Product Candidate, for the Treatment of Solid Tumors
August 24, 2023 08:00 ET
|
NKGen Biotech, Inc.
SANTA ANA, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of...
Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Effectiveness of Form S-4 for Proposed Business Combination
August 15, 2023 12:07 ET
|
NKGen Biotech, Inc.
Special Meeting of Graf Stockholders to Approve Proposed Business Combination to be Held on August 30, 2023 Post-Combination Company’s Securities to be Listed on Nasdaq Under Ticker Symbols “NKGN”...